期刊
MOLECULAR PHARMACEUTICS
卷 9, 期 6, 页码 1705-1716出版社
AMER CHEMICAL SOC
DOI: 10.1021/mp3000309
关键词
PEG-PCL micelle; TGX-221; PSMA; target delivery
资金
- Congressionally Directed Medical Research Program IDEA Award in Prostate Cancer [KAN0061569]
- DOD [W81XWH-09-1-0455]
- Kansas Academy of Science
TGX-221 is a potent, selective, and cell membrane permeable inhibitor of the PI3K p110 beta catalytic subunit. Recent studies showed that TGX-221 has anti-proliferative activity against PTEN-deficient tumor cell lines including prostate cancers. The objective of this study was to develop an encapsulation system for parenterally delivering TGX-221 to the target tissue through a prostate-specific membrane aptamer (PSMAa10) with little or no side effects. In this study, PEG-PCL micelles were formulated to encapsulate the drug, and a prodrug strategy was pursued to improve the stability of the carrier system. Fluorescence imaging studies demonstrated that the cellular uptake of both drug and nanoparticles was significantly improved by targeted micelles in a PSMA positive cell line. The area under the plasma concentration time curve of the micelle formulation in nude mice was 2.27-fold greater than that of the naked drug, and the drug clearance rate was 6.16-fold slower. These findings suggest a novel formulation approach for improving site-specific drug delivery of a molecular-targeted prostate cancer treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据